![Time course of the sensitivity and specificity of anti-SARS-CoV-2 IgM and IgG antibodies for symptomatic COVID-19 in Japan | Scientific Reports Time course of the sensitivity and specificity of anti-SARS-CoV-2 IgM and IgG antibodies for symptomatic COVID-19 in Japan | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-021-82428-5/MediaObjects/41598_2021_82428_Fig1_HTML.png)
Time course of the sensitivity and specificity of anti-SARS-CoV-2 IgM and IgG antibodies for symptomatic COVID-19 in Japan | Scientific Reports
![Frontiers | Detection of Impaired IgG Antibody Formation Facilitates the Decision on Early Immunoglobulin Replacement in Hypogammaglobulinemic Patients Frontiers | Detection of Impaired IgG Antibody Formation Facilitates the Decision on Early Immunoglobulin Replacement in Hypogammaglobulinemic Patients](https://www.frontiersin.org/files/Articles/122614/fimmu-06-00032-HTML/image_m/fimmu-06-00032-t003.jpg)
Frontiers | Detection of Impaired IgG Antibody Formation Facilitates the Decision on Early Immunoglobulin Replacement in Hypogammaglobulinemic Patients
![Frontiers | Role of the Aspergillus-Specific IgG and IgM Test in the Diagnosis and Follow-Up of Chronic Pulmonary Aspergillosis Frontiers | Role of the Aspergillus-Specific IgG and IgM Test in the Diagnosis and Follow-Up of Chronic Pulmonary Aspergillosis](https://www.frontiersin.org/files/MyHome%20Article%20Library/441903/441903_Thumb_400.jpg)
Frontiers | Role of the Aspergillus-Specific IgG and IgM Test in the Diagnosis and Follow-Up of Chronic Pulmonary Aspergillosis
![Frontiers | Declining Levels of Neutralizing Antibodies Against SARS-CoV-2 in Convalescent COVID-19 Patients One Year Post Symptom Onset Frontiers | Declining Levels of Neutralizing Antibodies Against SARS-CoV-2 in Convalescent COVID-19 Patients One Year Post Symptom Onset](https://www.frontiersin.org/files/MyHome%20Article%20Library/708523/708523_Thumb_400.jpg)
Frontiers | Declining Levels of Neutralizing Antibodies Against SARS-CoV-2 in Convalescent COVID-19 Patients One Year Post Symptom Onset
![Cells | Free Full-Text | Differences in the Concentration of Anti-SARS-CoV-2 IgG Antibodies Post-COVID-19 Recovery or Post-Vaccination Cells | Free Full-Text | Differences in the Concentration of Anti-SARS-CoV-2 IgG Antibodies Post-COVID-19 Recovery or Post-Vaccination](https://www.mdpi.com/cells/cells-10-01952/article_deploy/html/images/cells-10-01952-g001.png)
Cells | Free Full-Text | Differences in the Concentration of Anti-SARS-CoV-2 IgG Antibodies Post-COVID-19 Recovery or Post-Vaccination
![Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study - The Lancet Microbe Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study - The Lancet Microbe](https://www.thelancet.com/cms/asset/18f48ea1-5898-49ea-9426-efaeeacd7d30/gr1.jpg)
Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study - The Lancet Microbe
![Detection of IgM and IgG antibodies in patients with coronavirus disease 2019 - Hou - 2020 - Clinical & Translational Immunology - Wiley Online Library Detection of IgM and IgG antibodies in patients with coronavirus disease 2019 - Hou - 2020 - Clinical & Translational Immunology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/ae0b156a-70d4-41de-943a-2173876db40c/cti21136-fig-0001-m.jpg)
Detection of IgM and IgG antibodies in patients with coronavirus disease 2019 - Hou - 2020 - Clinical & Translational Immunology - Wiley Online Library
![Dynamic changes and prevalence of SARS-CoV-2 IgG/IgM antibodies: Analysis of multiple factors - International Journal of Infectious Diseases Dynamic changes and prevalence of SARS-CoV-2 IgG/IgM antibodies: Analysis of multiple factors - International Journal of Infectious Diseases](https://www.ijidonline.com/cms/asset/3150c325-6232-49e0-b6f4-21963d85c399/gr1.jpg)
Dynamic changes and prevalence of SARS-CoV-2 IgG/IgM antibodies: Analysis of multiple factors - International Journal of Infectious Diseases
Pan-HSV-2 IgG Antibody in Vaccinated Mice and Guinea Pigs Correlates with Protection against Herpes Simplex Virus 2 | PLOS ONE
![Performance evaluation of four type-specific commercial assays for detection of herpes simplex virus type 1 antibodies in a Middle East and North Africa population - ScienceDirect Performance evaluation of four type-specific commercial assays for detection of herpes simplex virus type 1 antibodies in a Middle East and North Africa population - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S138665321830074X-gr3.jpg)
Performance evaluation of four type-specific commercial assays for detection of herpes simplex virus type 1 antibodies in a Middle East and North Africa population - ScienceDirect
![Immunoglobulin test results: When to take action and when to provide reassurance | New Zealand Doctor Immunoglobulin test results: When to take action and when to provide reassurance | New Zealand Doctor](https://www.nzdoctor.co.nz/sites/default/files/2021-09/Table_1_From_The_Lab.jpg)
Immunoglobulin test results: When to take action and when to provide reassurance | New Zealand Doctor
![Detection of persistent SARS-CoV-2 IgG antibodies in oral mucosal fluid and upper respiratory tract specimens following COVID-19 mRNA vaccination | Scientific Reports Detection of persistent SARS-CoV-2 IgG antibodies in oral mucosal fluid and upper respiratory tract specimens following COVID-19 mRNA vaccination | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-021-03931-3/MediaObjects/41598_2021_3931_Fig1_HTML.png)
Detection of persistent SARS-CoV-2 IgG antibodies in oral mucosal fluid and upper respiratory tract specimens following COVID-19 mRNA vaccination | Scientific Reports
![Neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independently of symptoms in adults | Communications Medicine Neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independently of symptoms in adults | Communications Medicine](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs43856-021-00012-4/MediaObjects/43856_2021_12_Fig1_HTML.png)